We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Iatrogenic Microplastic Exposure: A Possible and Underrecognized Healthcare-Associated Exposure Framework in Human Medicotoxicological Risk
AI summary Read the abstract
Medical interventions—including intravenous fluids, implantable devices, and polymer-coated oral medications—represent an underrecognized fourth route of microplastic and nanoplastic exposure, with vulnerable populations such as neonates and ICU patients facing disproportionate risk. This conceptual review calls for re-evaluation of plastic use in healthcare settings to reduce iatrogenic nanoplastic burden in patients.
Microplastics (MPs) are emerging environmental contaminants detected not only in water, soil, and air but also in human biological samples. To date, three main exposure routes have been identified. Currently, the principal exposure routes examined in scholarly works are oral, inhalational, and dermal. This paper explores iatrogenic microplastic exposure (IME) as an underrecognized healthcare-associated source of exposure and suggests that, in certain clinical contexts involving invasive, device-mediated, or direct systemic contact, IME may be considered a possible fourth route of exposure. IME is the introduction of microplastics into the human body through medical interventions. A literature-based conceptual review was conducted focusing on the materials and additives used in pharmaceutical formulations, intravenous systems, and medical devices. Particular attention was given to polymer-based excipients and plasticizers (e.g., phthalates, PEG, triacetin) found in enteric drug coatings and infusion packaging. Findings suggest that polymer-derived particles may enter systemic circulation via intravenous fluids, implantable devices, or oral medications, especially under conditions of heat, pressure, or prolonged contact. Such materials, though deemed biocompatible, may contribute to nanoplastic load and chronic exposure risks. Vulnerable groups such as neonates, oncology patients, and ICU populations may face disproportionate exposure. This calls for re-evaluation of plastic use in medical practice, improved regulatory oversight of pharmaceutical excipients, and innovation in plastic-free biomedical materials. Integrating this route into toxicological and epidemiological frameworks will enrich our understanding of microplastic-related health risks and broaden the scope of environmental health strategies.
More Papers Like This
Plastic particles in medicine: A systematic review of exposure and effects to human health
AI summary Read the abstract
Medical plastics including bags, containers, and administration sets release micro- and nanoplastics along with chemical additives that can interact with pharmaceutical constituents, creating an understudied route of direct human exposure. Both primary exposure (during medical treatment) and secondary environmental exposure (from hospital plastic waste disposal) represent potential health hazards.
Microplastic particles and infusion therapy — Evidence, implications, and unanswered questions
AI summary Read the abstract
This review highlights infusion therapy via medical devices and pharmaceutical containers as a significant but often overlooked route of microplastic exposure in humans. The study emphasizes that despite strict regulations, advances in clinical research have not been fully integrated into current industry testing standards, and calls for a standardized, multi-method approach to microplastic detection and risk assessment in medical settings.
Is intravenous infusion an unrecognized route for internal microplastic human exposure? A general assessment
AI summary Read the abstract
This study discovered that microplastics are present in intravenous (IV) infusion products used in hospitals, identifying a previously unrecognized route of microplastic exposure that bypasses the body's natural barriers. Standard IV filters removed some but not all of the plastic particles. This finding is important because IV-delivered microplastics go directly into the bloodstream, potentially posing a greater risk than microplastics that are eaten or inhaled.
Medical Microplastics: Research Progress on Exposure Pathways, Toxic Effects, and Detection Methods
AI summary Read the abstract
This study characterized anthropogenic microparticle deposition in Andean reservoirs, documenting plastic and non-plastic particle types and deposition rates at high-altitude water bodies. The findings reveal that remote South American mountain reservoirs receive microplastic inputs through atmospheric transport, with implications for Andean water supply quality.
Unraveling micro/nanoplastics and phthalates in infusion solutions: A novel integrated approach for quantification and cardiovascular cytotoxicity evaluation
AI summary Read the abstract
Researchers developed a new method to detect and measure micro- and nanoplastics in medical infusion solutions (IV bags) and found significant contamination in commonly used glucose and saline fluids. Nanoplastics dominated the contamination, with polyethylene, polypropylene, and polystyrene detected alongside phthalate chemicals that showed a strong correlation with plastic particle levels. The study suggests that IV therapy may be an overlooked route of direct plastic particle exposure into the bloodstream, and that combined exposure to nanoplastics and phthalates can have synergistic toxic effects on cardiovascular cells.
Research digests by email
When a large batch of papers lands in the Atlas, we read through it and send a short write-up of what stood out.